Analystreport

Blueprint Medicines Co. (NASDAQ: BPMC) is now covered by analysts at Stephens. They set an "overweight" rating and a $140.00 price target on the stock.

Blueprint Medicines Corporation  (BPMC) 
Last blueprint medicines corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com